Seeking Alpha
Profile| Send Message|
( followers)  

By Darnell Brown

This article will examine six of Warren Buffett's highest-yielding stock holdings. Warren Buffett is a legendary value investor and chairman of the board of Berkshire Hathaway (NYSE:BRK.A). Buffett led Berkshire from a textile company to a major holding corporation with a market cap of over $172 billion.

Glaxo Smith Kline PLC (NYSE:GSK)
Glaxo Smith Kline has a market cap of $106.65 billion, with a price-to-earnings ratio of 20.44. The stock has been trading in a 52-week range of between $36.28 and $45.34. The current stock price is $41.74. On July 26, the company reported second-quarter revenues of $10.8 billion compared to revenues of $10.5 billion in the second quarter of 2010. Net second-quarter income was $1.78 billion, up from $-4.55 million in the second quarter of 2010.

One of Glaxo Smith Kline’s primary competitors is Pfizer Inc. (NYSE:PFE), which is currently trading at $18.46. Pfizer Inc. has a market cap of $144.03 billion with a price to earnings ratio of 17.24. Pfizer Inc has a dividend yield of 4.30% versus Glaxo Smith Kline's dividend yield of 5.00%.

Warren Buffett's Berkshire Hathaway currently owns 1,510,500 shares of Glaxo Smith Kline. Berkshire Hathaway has made no recent trades of Glaxo Smith Kline. Glaxo Smith Kline is a company that investors can count on to be profitable. Investors can also count on Glaxo Smith Kline to provide a steady income flow. The company has paid dividends for many years, and over the last 5 years it has increased its dividend by 28%. For those who want a low risk-investment that will provide a reliable income flow, Glaxo Smith Kline is an excellent choice. I rate Glaxo Smith Kline PLC as a buy.

Conoco Phillips (NYSE:COP) Conoco Phillips has a market cap of $91.22 billion, with a price-to-earnings ratio of 8.38. The stock has traded in a 52-week range of between $53.59 and $81.80. The stock is currently trading at $66.44. On July 27, the company reported second-quarter revenues of $67.08 billion, compared to revenues of $50.1 billion in the second quarter of 2010. Second-quarter net income was $3.40 billion compared to $4.86 billion in the second quarter of 2010. Net income in 2010 increased to $11.48 billion from $4.86 in 2009.

One of Conoco Phillips' closest competitors is BP PLC (NYSE:BP), which is trading at $36.53. BP PLC has a market cap of $115.31 billion with a price-to-earnings ratio of 5.82. BP PLC pays a dividend which yields 4.60% compared to Conoco Phillips whose dividend yields 4.00%. Berkshire Hathaway owns 29,101,637 shares of Conoco Phillips. Berkshire Hathaway has made no recent trades of Conoco Phillips. Conoco Phillips increased its 2010 annual net income by 136%, and should be able to continue producing strong earnings results for as long as oil prices remain high. The company has also been an excellent dividend-paying stock, and over the last five years it has increased its dividend by 83%. I agree with Warren Buffett and think that Conoco Phillips is a stock worth owning. I rate Conoco Phillips as a buy.

Sanofi-Aventis SA (NYSE:SNY) Sanofi-Aventis has a market cap of $94.09 billion with a price-to-earnings ratio of 15.14. The stock has traded in a 52-week range of between $29.66 and $40.75. The current stock price is $35.05. The company reported 2010 revenues of $43.08 billion and net income of $7.33 billion, compared to 2009 revenues of $44.1 billion and net income of $7.55 billion.

One of Sanofi-Aventis' biggest competitors is Merck & Company Inc. (NYSE:MRK), which is trading at $32.37. Merck has a market cap of $99.73 billion with a price-to-earnings ratio of 34.88. Merck pays a dividend which yields 4.70% versus Sanofi-Aventis whose dividend yields 3.80%.

Berkshire Hathaway owns 4,063,675 shares of Sanofi-Aventis. Berkshire Hathaway has not made any recent trades of Sanofi-Aventis. Sanofi-Adventis has increased its dividend payout in each of the last three years. Sanofi-Adventis is a highly regarded French pharmaceutical company that has produced blockbuster drugs such as Plavix and Ambien. I think that Sanofi-Aventis is a solid investment, but I would prefer to own stock in a pharmaceutical company such as Merck & Company. I rate Sanofi Aventis SA as a hold.

M&T Bank Corporation (NYSE:MTB) M&T Bank Corporation has a market cap of $9.08 billion with a price-to-earnings ratio of 10.19. The stock has traded in a 52-week range of between $69.23 and $95.00. The current stock price is $72.29. On July 20th, the company reported revenues of $1.22 billion compared to second-quarter 2010 revenues of $981 million. Second-quarter net income was $322 million compared to net income of $189 million in the second quarter of 2010.

One of M&T Bank’s competitors is Key Corporation (NYSE:KEY), which is trading at $6.24. Key Corporation has a market cap of $5.95 billion with a price to earnings ratio of 6.53. Key Corporation pays a dividend yield of 1.90% versus M & T Bank whose dividend yields 3.70%.

Berkshire Hathaway owns 5,363,821 shares of M&T Bank. Berkshire Hathaway has not made any recent trades of this stock. M&T Bank has increased earnings in each of the last three years and made a 70% increase in net income in 2010 from 2009. M&T Bank has been a strong dividend-paying stock and has increased its dividend by 55.5% over the last five years. I rate M&T Bank Corporation as a buy.

General Electric Company (NYSE:GE) General Electric Company has a market cap of $167.06 billion with a price-to-earnings ratio of 12.40. The stock has traded in a 52-week range of between $14.82 and $21.65. The current stock price is $15.76. On July 22, the company reported second-quarter revenues of $35.6 billion compared to revenues of $37.4 billion in the second quarter of 2010. Second-quarter net income was $3.69 billion compared to net income of $3.11 billion in the second quarter of 2010.

One of General Electric’s biggest competitors is Siemens AG (SI), which trades at $98.51. Siemens AG has a market cap of $86.10 billion with a price to earnings ratio of 13.57. Siemens pay a dividend that yields 2.70% versus General Electric whose dividend yields 3.80%.

Berkshire Hathaway owns 7,777,900 shares of General Electric. Berkshire Hathaway has not made any recent trades of this stock. General Electric increased income by 14% over the second quarter of 2010. The company has a mixed dividend history but has increased dividends by 40% since 2010. General Electric is one of the largest companies in the world and is a part of many long-term investors' portfolios. I agree with Warren Buffett and think that this is a stock worth owning. I rate General Electric as a buy.

Johnson & Johnson (NYSE:JNJ) Johnson & Johnson has a market cap of $175.57 billion with a price-to-earnings ratio of 15.33. The stock has traded in a 52 week range of between $57.50 and $68.05. The current stock price is $64.07. On July 19th, the company reported revenues of $16.6 billion compared to revenues of $15.3 billion in the second quarter of 2010. Second quarter net income was $2.78 billion compared to net income of $3.45 billion in the second quarter of 2010.

One of Johnson & Johnson’s primary competitors is Novartis AG (NYSE:NVS), which is trading at $57.30. Novartis AG has a market cap of $139.04 billion with a price to earnings ratio of 13.52. Novartis AG pays a dividend which yields 3.50% versus Johnson & Johnson whose dividend yields 3.60%.

Berkshire Hathaway owns 39,836,642 shares of Johnson & Johnson. Berkshire Hathaway has not made any recent trades of this stock. In 2010, Johnson & Johnson grew net income by 24%. Johnson & Johnson has been an excellent dividend-paying company and has raised its annual dividend in each of the last 47 years. This is a stock for people who like to sleep well at night and not worry about their investments. Johnson & Johnson should be a part of any long-term investor's portfolio. I rate Johnson & Johnson as a buy.

Source: 6 Top-Yielding Stocks In Warren Buffett's Portfolio